243 related articles for article (PubMed ID: 23968379)
1. Emerging drugs for polycythemia vera.
Tibes R; Mesa RA
Expert Opin Emerg Drugs; 2013 Sep; 18(3):393-404. PubMed ID: 23968379
[TBL] [Abstract][Full Text] [Related]
2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
3. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
4. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
Reiter A; Harrison C
Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
[TBL] [Abstract][Full Text] [Related]
5. New Therapeutic Approaches in Polycythemia Vera.
Falchi L; Newberry KJ; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
[TBL] [Abstract][Full Text] [Related]
6. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
Nazha A; Khoury JD; Verstovsek S; Daver N
Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
Lengfelder E
Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
[TBL] [Abstract][Full Text] [Related]
8. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
9. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
[TBL] [Abstract][Full Text] [Related]
10. Polycythemia vera: current pharmacotherapy and future directions.
Hensley B; Geyer H; Mesa R
Expert Opin Pharmacother; 2013 Apr; 14(5):609-17. PubMed ID: 23480062
[TBL] [Abstract][Full Text] [Related]
11. Can pegylated interferon improve the outcome of polycythemia vera patients?
Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
[TBL] [Abstract][Full Text] [Related]
12. Current and future treatment options for polycythemia vera.
Griesshammer M; Gisslinger H; Mesa R
Ann Hematol; 2015 Jun; 94(6):901-10. PubMed ID: 25832853
[TBL] [Abstract][Full Text] [Related]
13. Polycythemia vera: aspects of its current diagnosis and initial treatment.
Silver RT; Abu-Zeinah G
Expert Rev Hematol; 2023 Apr; 16(4):253-266. PubMed ID: 37013802
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
Michiels JJ; Barbui T; Finazzi G; Fuchtman SM; Kutti J; Rain JD; Silver RT; Tefferi A; Thiele J
Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
[TBL] [Abstract][Full Text] [Related]
15. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
16. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
17. [Recent advances in polycythemia vera treatment].
Edahiro Y
Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
[TBL] [Abstract][Full Text] [Related]
18. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?
Vannucchi AM; Guglielmelli P
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):480-488. PubMed ID: 29222296
[TBL] [Abstract][Full Text] [Related]
19. Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.
Kremyanskaya M; Mascarenhas J; Hoffman R
Expert Opin Pharmacother; 2015 Jun; 16(8):1185-94. PubMed ID: 25873215
[TBL] [Abstract][Full Text] [Related]
20. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
Finazzi G; Barbui T
Leukemia; 2008 Aug; 22(8):1494-502. PubMed ID: 18596737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]